Log in

Sesen Bio Stock Forecast, Price & News

+0.07 (+5.69 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $1.30
50-Day Range
MA: $1.07
52-Week Range
Now: $1.30
Volume1.63 million shs
Average Volume1.37 million shs
Market Capitalization$152.32 million
P/E RatioN/A
Dividend YieldN/A
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Read More
Sesen Bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SESN



Sales & Book Value

Annual Sales$430,000.00
Book Value($0.26) per share


Net Income$-107,500,000.00


Market Cap$152.32 million
Next Earnings Date11/10/2020 (Estimated)
+0.07 (+5.69 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

How has Sesen Bio's stock been impacted by COVID-19 (Coronavirus)?

Sesen Bio's stock was trading at $0.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SESN stock has increased by 80.6% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Sesen Bio?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sesen Bio

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Sesen Bio

How were Sesen Bio's earnings last quarter?

Sesen Bio Inc (NASDAQ:SESN) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.15.
View Sesen Bio's earnings history

What price target have analysts set for SESN?

2 analysts have issued 1-year price objectives for Sesen Bio's shares. Their forecasts range from $2.25 to $5.00. On average, they anticipate Sesen Bio's stock price to reach $3.63 in the next year. This suggests a possible upside of 178.8% from the stock's current price.
View analysts' price targets for Sesen Bio

Who are some of Sesen Bio's key competitors?

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include XOMA (XOMA), Amarin (AMRN), VBI Vaccines (VBIV), Verastem (VSTM), Advanced Micro Devices (AMD), Micron Technology (MU), Opko Health (OPK), AVEO Pharmaceuticals (AVEO), Biocept (BIOC) and Rigel Pharmaceuticals (RIGL).

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the following people:
  • Mr. Richard F. Fitzgerald, CFO, Sec. & Treasurer (Age 55)
  • Dr. Thomas R. Cannell, Pres, CEO & Director (Age 57)
  • Dr. K. Christopher Garcia, Co-Founder & Member of Scientific Advisory Board
  • Dr. Gregory L. Verdine, Co-Founder (Age 60)
  • Dr. Casey T. Weaver, Co-Founder & Member of Scientific Advisory Board

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Bridgeway Capital Management Inc. (0.79%), Stratos Wealth Partners LTD. (0.18%), Bank of New York Mellon Corp (0.06%), Virtu Financial LLC (0.06%) and Two Sigma Advisers LP (0.04%).

Which institutional investors are selling Sesen Bio stock?

SESN stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp.

Which institutional investors are buying Sesen Bio stock?

SESN stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Stratos Wealth Partners LTD., Virtu Financial LLC, and Two Sigma Advisers LP.

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $1.30.

How big of a company is Sesen Bio?

Sesen Bio has a market capitalization of $152.32 million and generates $430,000.00 in revenue each year. The company earns $-107,500,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Sesen Bio employs 24 workers across the globe.

What is Sesen Bio's official website?

The official website for Sesen Bio is www.sesenbio.com.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-444-8550 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.